CGEM zipalertinib plus chemotherapy improves EGFR exon 20 NSCLC
In first-line EGFR exon 20 insertion mutation NSCLC, zipalertinib plus chemotherapy showed significantly improved median progression-free survival and response rates versus chemotherapy alone, with a manageable safety profile.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.